Skip to content

Ocular Comorbidity in Atopic Dermatitis

Ocular Comorbidity in Atopic Dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04973384
Enrollment
120
Registered
2021-07-22
Start date
2021-08-05
Completion date
2026-12-31
Last updated
2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Keratoconjunctivitis

Brief summary

A clinical characterization of a large cohort of patients with different severities of AD and ocular symptoms/atopic keratoconjunktivitis (AKC). The data will contribute to assess the frequency of complications in order to give a rationale for focused prevention and treatment strategy.

Detailed description

Atopic Dermatitis (AD), a very common inflammatory skin condition of child and adulthood, is strongly associated with ocular disease. Accordingly, about 20% experience conjunctivitis at some point, and many have chronic disease. Atopic keratoconjunctivitis (AKC) is the most feared as it may lead to blindness. Little is known about the etiology, the immune infiltrate, as well as predictive factors of AKC and the clinical characteristics of AD patients who develop this entity. We expect this project to enable clinicians to better identify AKC patients in the future as well as improve the understanding of the pathogenesis of AKC. The ocular findings will be compared between AD severity and a control group without ocular symptoms.

Interventions

None listed

Sponsors

Oslo University Hospital
CollaboratorOTHER
Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Danish talking * Diagnosed with atopic dermatitis (AD) * Current or previous ocular symptoms suspected to be atopic keratoconjunctivitis

Exclusion criteria

* No pause in eyedrops * Ocular infections within the last 3 months * Use of local or systemic antibiotics within the last 3 months * Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, previous cerebral infarction or bleeding, lung diseases and autoimmune diseases other than atopic dermatitis and related comorbidities. The diseases are accepted if they are well treated or do not require treatment * Current pregnant or breastfeeding * Use of contact lenses, unless these are paused 2 weeks before the examination or they are due to keratoconus treatment * If the eye symptoms turn out not to be related to atopic keratoconjunctivitis * If it is assessed that the individual cannot participate sufficiently for the examination

Design outcomes

Primary

MeasureTime frameDescription
Bulbar redness (BR) score1 day At examinationDifference in Bulbar redness (BR) score (Keratograph 5M, R-scan). Scale from 0-4. A higher score indicates more severe BR.

Secondary

MeasureTime frameDescription
Non-invasive Keratograph Break-Up Time (NIKBUT)1 day Cross-sectional at examination (one time)Difference in Non-invasive Keratograph Break-Up Time (NIKBUT) (Keratograph 5M)
Meibo-Scan1 day Cross-sectional at examination (one time)Difference in Meibo-Scan (Keratograph 5M). Scale from 0-3. A higher score indicates more morphological changes.
Ocular surface staining1 day Cross-sectional at examination (one time)Difference in Ocular surface staining
Osmolarity of the tears1 day Cross-sectional at examination (one time)Difference in Osmolarity of the tears (TearLab™)
Fluorescein tear break up time (TFBUT)1 day Cross-sectional at examination (one time)Difference in Fluorescein tear break up time (TFBUT)
Schirmer's I test1 day Cross-sectional at examination (one time)Difference in Schirmer's I test
Intraocular pressure (IOP)1 day Cross-sectional at examination (one time)Difference in Intraocular pressure (IOP)
Pentacam investigations for detection of keratoconus1 day Cross-sectional at examination (one time)Difference in the frequency of keratoconus
Tear cytokine analysis1 day Cross-sectional at examination (one time)Difference in the levels of inflammatory cytokines in the tears
Tear proteomic analysis1 day Cross-sectional at examination (one time)Difference in the protein profile in the tears
Inferior Tear Meniscus Height (TMH)1 day Cross-sectional at examination (one time)Difference in Inferior Tear Meniscus Height (TMH) (Keratograph 5M)
Goblet cell density1 day Cross-sectional at examination (one time)Difference in goblet cells density
Microbiome analysis1 day Cross-sectional at examination (one time)Difference in the amount of different species of the Microbiome of the ocular surface
Investigation of the infestation of Demodex1 day Cross-sectional at examination (one time)Difference in the amount of Demodex mites in the eyelashes/eyelids with non-invasive in vivo confocal microscopy
OSDI-score1 day Cross-sectional at examination (one time)Difference in the Ocular Surface Disease Index (OSDI) score. A 12-item questionnaire that gives a score on a scale from 0 to 100, where higher scores represent greater disability (mild \[13-22 points\], moderate \[23-32 points\], and severe \[33-100 points\]).
PO-SCORAD1 day Cross-sectional at examination (one time)Difference in the Patient-Oriented SCORing of Atopic Dermatitis (POSCORAD) score. A validated self-assessment tool to clinical evaluate AD severity, using subjective and objective criteria. A higher score indicates more severe AD.
POEM1 day Cross-sectional at examination (one time)Difference in the Patient Oriented Eczema Measure (POEM) score. A validated self-assessment tool to clinical evaluate AD severity. A scale from 0-28. A higher score indicates more severe AD.
EASI1 day Cross-sectional at examination (one time)Difference in Eczema Area and Severity Index (EASI) score. A tool used to measure the extent (area) and severity of atopic eczema. A scale from 0-72. A higher score indicates more severe AD.
best-corrected logMAR acuity1 day Cross-sectional at examination (one time)Difference in best-corrected logMAR acuity
Slit lamp examination1 day Cross-sectional at examination (one time)Difference in observations with slit lamp
Tear MUC5AC analysis1 day Cross-sectional at examination (one time)Difference in the level of MUC5AC in tears

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026